Extended Data Fig. 8: Summary of differentially abundant microbiome features by clinical variables and outcomes including all specimens collected in the 3-weeks pre-infusion period. | Nature Medicine

Extended Data Fig. 8: Summary of differentially abundant microbiome features by clinical variables and outcomes including all specimens collected in the 3-weeks pre-infusion period.

From: A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Extended Data Fig. 8: Summary of differentially abundant microbiome features by clinical variables and outcomes including all specimens collected in the 3-weeks pre-infusion period.

Heatmaps showing the associations between the species (a) and metabolic pathways (b) of the baseline gut microbiome and clinical parameters and major outcomes (Mann–Whitney tests, p-value < 0.05). Color indicates the Log10 of the following ratios: age (>= 65 / < 65 years), country (Germany / US), ECOG (grades 0-1 / 2-3), LDH (LDH at lymphodepletion chemotherapy: >= 280 / < 280 U ml-1), HR antibiotic exposures (no / yes), response (CR / no CR at day 180), survival (alive / dead at day 180), early progression (lymphoma progression until day 180 / progression > 180 days or no progression during follow-up) and CRS (grades < =1 / >1). Associations with P-value > 0.05 or with absolute log2 fold-change < 1 were set on the heatmap to have a log10 fold-change of zero.

Back to article page